What Is SS-31?

1. How does SS-31 work?

Mitochondria convert energy from food into ATP through a series of reactions along their inner membrane. That membrane folds into structures called cristae. Its shape and the arrangement of its proteins affect how well energy production works.

Cardiolipin helps maintain this arrangement. In Birk and colleagues’ experiments, SS-31 interacted with cardiolipin and protected mitochondria exposed to interrupted blood supply. The researchers studied molecular mechanisms and kidney injury in rats; they did not test athletic recovery.

Further experiments from the same group examined cytochrome c, a protein that transfers electrons during ATP production. Its interaction with cardiolipin can also give it an activity that promotes oxidative damage. SS-31 helped preserve electron transfer while limiting that damaging activity in the experimental systems.

This explains why descriptions such as “mitochondrial antioxidant” only partly describe SS-31. Its relationship with the membrane and its proteins is central to the research. But improving an isolated mitochondrial process cannot tell you how much faster someone will run, how much fatigue they will feel or whether they will live longer.

2. SS-31 human studies: what did researchers measure?

The human studies below involve very different starting points: older muscle selected for low mitochondrial function, inherited mitochondrial myopathy, and Barth syndrome. Results from one population cannot supply an expected benefit for the others.

The ATP study behind the energy claims

Roshanravan and colleagues selected older adults with low mitochondrial function. After a two-hour infusion, average ATP production capacity rose 27% from baseline with elamipretide and 12% with placebo. Those percentages describe changes within each group. They do not mean participants had 27% more energy throughout the day.

The statistical result was borderline: the percentage-change comparison reached P = 0.045, while the absolute-change comparison gave P = 0.055. By day seven, the groups no longer differed. Measured fatigue resistance in the small hand muscle did not significantly improve.

That is a short-term physiological signal worth studying, with no demonstrated performance gain in that experiment. The trial also cannot establish what repeated subcutaneous injections do in a younger athlete whose mitochondrial function is already normal.

The larger trial did not improve walking or fatigue

In MMPOWER-3, 218 participants received either elamipretide or placebo for 24 weeks. The difference in six-minute walking distance was −3.2 metres, with a 95% confidence interval from −18.7 to +12.3 metres. Fatigue also failed to improve significantly.

The trial tested people with genetically confirmed primary mitochondrial myopathy. It cannot rule out every effect in every population, but it provides no support for a broad promise that targeting mitochondria reliably improves stamina. A larger controlled test can fail even when earlier experiments offer plausible mechanisms and encouraging signals.

3. Is SS-31 FDA approved? What Forzinity’s approval means

On September 19, 2025, the FDA granted Forzinity accelerated approval for Barth syndrome in patients weighing at least 30 kg. The approval concerns improved muscle strength in this rare mitochondrial disease. It does not cover ordinary fatigue, bodybuilding or anti-aging.

Barth syndrome involves defects in the gene for tafazzin, which helps remodel cardiolipin. That gives elamipretide a disease-specific rationale. In the published randomized trial, neither walking distance nor the symptom-score primary endpoint improved significantly. An extension in which everyone received the drug reported improvements over time, but lacked a concurrent placebo group.

The FDA based accelerated approval on knee extensor strength, a measure considered reasonably likely to predict patient benefit. It required a confirmatory randomized trial. Readers should therefore distinguish the medical approval, the evidence supporting it, and a claim that the same molecule improves healthy aging.

A research vial labeled “SS-31” is also a separate product. The name alone cannot establish that its identity, strength, sterility or formulation matches the approved medicine.

4. SS-31 for longevity, endurance and recovery

The Campbell mouse study helps explain the longevity interest. Eight weeks of treatment improved mitochondrial energy production, reduced measures of oxidative stress and improved exercise tolerance in aged mice. The experiment connects cellular changes with physical function in an aging animal.

It does not establish human lifespan extension. Nor does an improvement in an old mouse imply an equivalent gain in a well-trained person. Starting mitochondrial function, disease, species and the outcome being measured can all change the result.

For endurance, the human findings above are more restrained than the mouse findings. The older-adult experiment found no significant fatigue-resistance benefit, and MMPOWER-3 found no walking benefit. Neither establishes higher VO₂ max, faster race times or better recovery between lifting sessions in healthy athletes.

Claims about “mitochondrial repair” also need a defined measurement. ATP capacity, muscle strength, symptoms and survival are different outcomes. A favorable result for one should keep its original name rather than becoming a promise about all four.

What about fat loss or GLP-1-related fatigue?

The cited trials do not establish a human fat-loss effect or a treatment for fatigue during tirzepatide or semaglutide use. Greater ATP production capacity does not demonstrate increased daily calorie expenditure, appetite suppression or muscle retention during a calorie deficit.

A personal log showing less fatigue after adding SS-31 cannot separate its effect from changes in food intake, sleep, training or other treatments. Persistent fatigue deserves an assessment of its cause before it is attributed to mitochondrial dysfunction.

5. SS-31 vs MOTS-c vs NAD+

All three appear in discussions of cellular energy, but they act at different points and have different evidence.

There is no established head-to-head human result showing that SS-31 outperforms MOTS-c for endurance or longevity. More clinical development makes SS-31 better characterized, but does not answer that comparison.

“SS-31 first, MOTS-c afterward” is sometimes presented as a sequence of repairing mitochondria before stimulating them. The studies cited here did not test that sequence. They also did not establish added benefit from an SS-31, MOTS-c and NAD+ stack. Different mechanisms supply a hypothesis for a combination trial, without supplying its result.

6. SS-31 dosage, cycles and half-life

The Forzinity prescribing information specifies 40 mg subcutaneously once daily for eligible Barth syndrome patients, with dose reduction in adults with severe renal impairment. This is a disease-specific prescription regimen.

No trial discussed here validates a dose, loading phase or maintenance cycle for healthy aging. A lower amount repeated across forums is not an established effective dose; a larger clinical dose does not make escalation a sound experiment either. The intended outcome and the studied population belong beside any dosage number.

For pharmacokinetics, the label reports about 92% subcutaneous bioavailability and peak concentrations within 0.5–1 hour. It describes urinary elimination of elamipretide and its metabolites. Time to peak is different from half-life, which describes how concentrations decline.

A half-life estimate needs a specified product, route and population. It cannot by itself determine how long a functional benefit lasts or how often to repeat treatment. The intravenous older-adult experiment also cannot establish the absorption or effects of an oral SS-31 product.

7. SS-31 side effects and product quality

In the Forzinity label’s 12-person crossover trial, local reactions occurred in 100% during elamipretide treatment versus 67% during placebo. Pain occurred in 75% versus 42%. These are small-sample estimates. The label also warns about serious hypersensitivity reactions.

A treatment can be tolerable enough to study without having a favorable benefit-risk balance for a healthy person. Without an established performance benefit, injection discomfort, allergic reactions and uncertain long-term outcomes still count against the decision.

Product quality adds another question. A certificate showing chemical purity does not, by itself, establish the sterility or endotoxin content of the finished injectable. Research-product labeling also cannot transfer the clinical findings of a pharmaceutical preparation to another manufacturer’s vial.

8. What can you measure meaningfully?

The ATP trial used magnetic resonance spectroscopy to assess muscle energy production. A wearable’s recovery score, a subjective energy rating and a blood NAD+ result measure different things. None can verify that SS-31 bound cardiolipin or repaired mitochondrial membranes.

For an interpretable record, define the outcome before reviewing it: pace at a fixed workload, repeated strength performance, fatigue during a standard activity or a symptom relevant to clinical care. Record sleep, training load, food intake, illness and medication changes alongside it. These details help explain why a result might change; they do not turn self-experimentation into a controlled trial.

If several compounds start at once, the log cannot identify which caused an improvement or a reaction. The peptide tracking guide covers ways to keep ingredient names, dates, symptoms and outcomes together so those records remain usable when discussing them with a clinician.

9. SS-31 FAQ

• What is SS-31 used for?

  SS-31 is the research name for elamipretide. Its prescription product, Forzinity, has a narrow approval for Barth syndrome. People also discuss it for energy, endurance and longevity, but those broader benefits remain unestablished.

• Is SS-31 FDA approved?

  Forzinity received accelerated FDA approval in September 2025 for patients with Barth syndrome weighing at least 30 kg. This does not make online research SS-31 products approved medicines or establish their quality.

• Does SS-31 increase ATP?

  A small randomized study in older adults with low mitochondrial function found an immediate ATP-capacity signal after an infusion. Muscle fatigue resistance did not significantly improve. An ATP measurement cannot predict a gain in daily energy or training performance.

• Does SS-31 help with weight loss?

  SS-31 has no established human weight-loss effect. Mitochondrial ATP production is different from reducing appetite or body fat, and the studies discussed here do not establish a fat-loss percentage.

• What is the SS-31 dosage for longevity?

  No human trial has validated a longevity dose, cycle or maintenance schedule. The prescription regimen for Barth syndrome addresses a specific disease and cannot supply an anti-aging protocol.

• What are SS-31's side effects?

  Injection-site reactions are common in clinical studies. Serious allergic reactions have also been reported. Safety findings from a defined pharmaceutical product cannot establish the safety of a separately manufactured research vial.

• What is the half-life of SS-31?

  Half-life depends on the formulation, route and population studied. The Forzinity label reports peak blood concentrations 0.5–1 hour after subcutaneous administration; that is time to peak, not half-life. Clearance data cannot establish a longevity dosing interval.

• Is SS-31 better than MOTS-c?

  SS-31 has substantially more clinical drug-development evidence. MOTS-c has a different proposed role in metabolic signaling. There is no head-to-head human trial establishing which improves healthy-user performance, or whether combining them adds benefit.

10. Sources